×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Ipsen to acquire Epizyme, expanding its portfolio in oncology
Ipsen
Ipsen to acquire Epizyme, expanding its portfolio in oncology · Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class...
22 months ago
Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
Yahoo Movies Canada
Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.
1 day ago
Carl Goldfischer Is The Independent Director of Epizyme, Inc. (NASDAQ:EPZM) And Just Spent US$60k On Shares
Yahoo News UK
Whilst it may not be a huge deal, we thought it was good to see that the Epizyme, Inc. (NASDAQ:EPZM) Independent...
2 days ago
Dire straits detailed for Epizyme before buyout by Ipsen
Fierce Pharma
As its stock price plummeted early this year, what did Massachusetts biotech Epizyme do to try to stop the bleeding? In a Tuesday SEC filing...
21 months ago
Epizyme trims workforce, pipeline for FDA-approved cancer drug Tazverik in cost-saving move
Fierce Biotech
Epizyme is cutting 12% of its staff and ending two clinical studies, including mid- and early-stage combo trials for the FDA-approved cancer...
26 months ago
WilmerHale Represents Epizyme In Deal With Ipsen
WilmerHale
WilmerHale is representing Epizyme, a fully integrated, commercial-stage biopharmaceutical company, in its acquisition by Ipsen.
22 months ago
Ipsen’s $247M Epizyme acquisition brings approved cancer drug & more in pipeline
MedCity News
Ipsen is paying $247 million to acquire Epizyme, a cancer drug developer with one FDA-approved product: follicular lymphoma therapy Tazverik.
22 months ago
Ipsen Snags Epizyme and Cancer Portfolio for a Cool $247M
BioSpace
Ipsen snapped up Cambridge, MA-based Epizyme for $247 million, plus a contingent value right (CVR) of 30 cents per share. The CVR will...
22 months ago
Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz ...
GlobeNewswire
The emergence of new products in the pipeline will add to the soft tissue sarcoma market growth in the future.
9 months ago